Insider Cluster (2 insiders) ·Filed Apr 1, 2026

VIR

Vir Biotechnology, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $864K total
Actionable Insight ▼ Bearish

The CEO's material sale—over three times the size of the director's—raises questions about confidence in near-term prospects. Traders should monitor upcoming earnings or clinical trial updates for potential negative catalysts.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
VIR ▲ +15.08% at T+60d
SHORT call ✗ call lost -15.08% · α vs SPY -1.70% · entry $9.02 → $10.38
Entry anchored
Mar 31, 03:59 PM ET
via exchange tick
T+1d
+0.44%
call -0.44% · α -0.36%
$9.06
settled 6mo ago
T+5d
+8.98%
call -8.98% · α -5.21%
$9.83
settled 6mo ago
T+20d
+11.75%
call -11.75% · α -2.03%
$10.08
settled 5mo ago
T+60d
+15.08%
call -15.08% · α -1.70%
$10.38
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Vir Biotechnology's CEO and a board director collectively sold $864K worth of shares in the past week, with the CEO accounting for 77% of the total volume. The sales occurred at market prices and represent open-market transactions, not automatic or non-cash dispositions.

Key Financial Metrics

Direction
selling
Total Value
$864.0K
Insiders
2

Key Facts

  • CEO Marianne De Backer sold 72,559 shares for $664,350 at $9.156 per share on April 6, 2026.
  • Director Vicki Sato sold 22,000 shares for $199,617 at $9.0735 per share on April 1, 2026.
  • Total insider selling cluster: $864K over a 7-day period.
  • All transactions were open-market sales (Form 4 code 'S'), indicating intentional divestment.

Financial Impact

$864K in insider sales over 7 days, representing 0.066% of the company's $1.3B market cap

insider ownershipmarket sentiment

Risk Factors

  • Insider selling, especially by the CEO, may signal reduced confidence in future performance or valuation.
  • Potential for negative market perception, particularly if no clear rationale (e.g., diversification) is disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VIR-1775595151995
18 reports for VIR
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +10.12%Feb 24, 2026
Filters
Rows
Reports for VIR — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$9.24 $9.78▲ +5.84%▲ +7.21%$11.17 (+20.89%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$8.89 $9.39▲ +5.62%▲ +5.67%$11.17 (+25.65%)
Jul 24, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$8.69 $8.90▲ +2.42%▲ +2.04%$11.17 (+28.54%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 2/10
$10.38 $10.02▼ −3.47%▼ −4.86%$11.17 (+7.61%)
Jun 10, 2026
16w ago
3
NEUTRAL ★ 1/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 10, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.77 $8.25▼ −5.93%▼ −2.11%$11.17 (+27.37%)
May 28, 2026
18w ago
8-K
NEUTRAL ★ 2/10
$9.55 $8.77▼ −8.17%▼ −8.12%$11.17 (+16.96%)
Apr 16, 2026
24w ago
DEFA14A
NEUTRAL ★ 3/10
$10.33 $10.35▲ +0.19%▼ −0.79%$11.17 (+8.13%)
Apr 10, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$9.31 $11.09▲ +19.12%▲ +15.82%$11.17 (+19.98%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 7, 2026